426 related articles for article (PubMed ID: 26167872)
21. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.
Zhang J; Zhou Q; Xie K; Cheng L; Peng S; Xie R; Liu L; Zhang Y; Dong W; Han J; Huang M; Chen Y; Lin T; Huang J; Chen X
J Exp Clin Cancer Res; 2021 Jun; 40(1):203. PubMed ID: 34154613
[TBL] [Abstract][Full Text] [Related]
22. Initiation of MLL-rearranged AML is dependent on C/EBPα.
Ohlsson E; Hasemann MS; Willer A; Lauridsen FK; Rapin N; Jendholm J; Porse BT
J Exp Med; 2014 Jan; 211(1):5-13. PubMed ID: 24367003
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region.
Sakamoto K; Imamura T; Yano M; Yoshida H; Fujiki A; Hirashima Y; Hosoi H
Blood Cancer J; 2014 Apr; 4(4):e205. PubMed ID: 24769646
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.
Karatas H; Li Y; Liu L; Ji J; Lee S; Chen Y; Yang J; Huang L; Bernard D; Xu J; Townsend EC; Cao F; Ran X; Li X; Wen B; Sun D; Stuckey JA; Lei M; Dou Y; Wang S
J Med Chem; 2017 Jun; 60(12):4818-4839. PubMed ID: 28603984
[TBL] [Abstract][Full Text] [Related]
25. Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.
Li DD; Wang ZH; Chen WL; Xie YY; You QD; Guo XK
Bioorg Med Chem; 2016 Nov; 24(22):6109-6118. PubMed ID: 27720555
[TBL] [Abstract][Full Text] [Related]
26. The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression.
Kuo YY; Hou HA; Chen YK; Li LY; Chen PH; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Chou WC; Liu CY; Tang JL; Yao M; Tien HF
Haematologica; 2014 Dec; 99(12):1799-807. PubMed ID: 25193961
[TBL] [Abstract][Full Text] [Related]
27. Myeloid transformation by
Wesolowski R; Kowenz-Leutz E; Zimmermann K; Dörr D; Hofstätter M; Slany RK; Mildner A; Leutz A
Life Sci Alliance; 2021 Jan; 4(1):. PubMed ID: 33144337
[TBL] [Abstract][Full Text] [Related]
28. C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia.
Hughes JM; Legnini I; Salvatori B; Masciarelli S; Marchioni M; Fazi F; Morlando M; Bozzoni I; Fatica A
Oncotarget; 2015 Jul; 6(21):18534-44. PubMed ID: 26053097
[TBL] [Abstract][Full Text] [Related]
29. A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis.
Li A; Yang Y; Gao C; Lu J; Jeong HW; Liu BH; Tang P; Yao X; Neuberg D; Huang G; Tenen DG; Chai L
J Clin Invest; 2013 Oct; 123(10):4195-207. PubMed ID: 24051379
[TBL] [Abstract][Full Text] [Related]
30. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
Chen W; Chen X; Li D; Wang X; Long G; Jiang Z; You Q; Guo X
Eur J Med Chem; 2021 Nov; 223():113677. PubMed ID: 34225179
[TBL] [Abstract][Full Text] [Related]
31. Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.
Li DD; Chen WL; Xu XL; Jiang F; Wang L; Xie YY; Zhang XJ; Guo XK; You QD; Sun HP
Eur J Med Chem; 2016 Aug; 118():1-8. PubMed ID: 27116709
[TBL] [Abstract][Full Text] [Related]
32. Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.
Jakobsen JS; Laursen LG; Schuster MB; Pundhir S; Schoof E; Ge Y; d'Altri T; Vitting-Seerup K; Rapin N; Gentil C; Jendholm J; Theilgaard-Mönch K; Reckzeh K; Bullinger L; Döhner K; Hokland P; Fitzgibbon J; Porse BT
Sci Adv; 2019 Jul; 5(7):eaaw4304. PubMed ID: 31309149
[TBL] [Abstract][Full Text] [Related]
33. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
34. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
[TBL] [Abstract][Full Text] [Related]
36. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.
Karatas H; Townsend EC; Cao F; Chen Y; Bernard D; Liu L; Lei M; Dou Y; Wang S
J Am Chem Soc; 2013 Jan; 135(2):669-82. PubMed ID: 23210835
[TBL] [Abstract][Full Text] [Related]
37. An evolutionarily conserved PTEN-C/EBPalpha-CTNNA1 axis controls myeloid development and transformation.
Fu CT; Zhu KY; Mi JQ; Liu YF; Murray ST; Fu YF; Ren CG; Dong ZW; Liu YJ; Dong M; Jin Y; Chen Y; Deng M; Zhang W; Chen B; Breslin P; Chen SJ; Chen Z; Becker MW; Zhu J; Zhang JW; Liu TX
Blood; 2010 Jun; 115(23):4715-24. PubMed ID: 20371743
[TBL] [Abstract][Full Text] [Related]
38. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
39. Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations.
Volpe G; Cauchy P; Walton DS; Ward C; Blakemore D; Bayley R; Clarke ML; Schmidt L; Nerlov C; Garcia P; Dumon S; Grebien F; Frampton J
Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30877232
[TBL] [Abstract][Full Text] [Related]
40. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
Cao F; Townsend EC; Karatas H; Xu J; Li L; Lee S; Liu L; Chen Y; Ouillette P; Zhu J; Hess JL; Atadja P; Lei M; Qin ZS; Malek S; Wang S; Dou Y
Mol Cell; 2014 Jan; 53(2):247-61. PubMed ID: 24389101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
